Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 Cash-to-Debt is 230.70 as of Jun. 2026, which is 17% above its 10-year median of 197.19. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 982 Drug Manufacturers companies, PRF Technologies ranks better than 91.24% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PRF Technologies's cash to debt ratio for the quarter that ended in Jun. 2026 was 230.70.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PRF Technologiescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for PRF Technologies's Cash-to-Debt or its related term are showing as below:
PRFX'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 197.19 Max: No Debt
Current: 230.7
During the past 8 years, PRF Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 197.19.
PRFX's Cash-to-Debt is ranked better than 91.24% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.965
vs PRFX: 230.70
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
PRF Technologies Cash-to-Debt Related Terms
PRF Technologies Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for PRF Technologies's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where PRF Technologies's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRF Technologies (PRFX) has a Cash-to-Debt of 230.70 as of Jun. 2026. This is 17% above median its historical median of 197.19. Over the past decade, PRF Technologies' Cash-to-Debt has ranged from 0.01 to 10,000.00. According to the industry distribution chart, PRF Technologies ranks #86 out of 982 companies in the Drug Manufacturers industry, placing it in the top 8.8%.
Is PRF Technologies' Cash-to-Debt too high?
PRF Technologies' current Cash-to-Debt of 230.70 is 17% above median its 10-year median of 197.19. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.97. PRF Technologies' value of 230.70 is 23806.7% above this industry median. Based on the distribution chart, PRF Technologies ranks #86 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' Cash-to-Debt compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #86 out of 982 companies for Cash-to-Debt. This places PRF Technologies in the top 9% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.97. PRF Technologies' value of 230.70 is 23806.7% above this benchmark. Historically, PRF Technologies' own Cash-to-Debt has ranged from 0.01 to 10,000.00 over the past decade. While the company's 10-year median is 197.19 vs. the industry median of 0.97, PRF Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.97, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current Cash-to-Debt of 230.70 is 23806.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current Cash-to-Debt is 230.70, which is 17% above median its own 10-year median of 197.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current Cash-to-Debt of 230.70. The current Cash-to-Debt is 230.70, which is 17% above median its 10-year median of 197.19 and 23806.7% above the Drug Manufacturers industry median of 0.97. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For PRF Technologies (PRFX), the current Cash-to-Debt is 230.70 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
